In the last month, Ms. Stryker sold around 132,000 shares valued at around $13.12 million. She now owns 25.96 million shares, worth around 6.81 percent of the company’s total market cap.
Here are five things to know:
1. Unloading the shares could mean Ms. Stryker expects the stock price to decline. More than 20 top stock analysts following the company listed the EPS expectations at $5.10 with a price-earnings ratio of 19.77.
2. There are 37 investment managers with Stryker stock in their Top 10, with Greenleaf Trust as the most positive institutional investor, according to the report. Greenleaf owned 29.02 million shares at the end of last year, 79.26 percent of the business.
3. The institutional ownership was 72 percent of the stock’s outstanding shares in the fourth quarter of 2014, which decreased by 7.85 million total shares they hold. The institutional investors owned 271.5 million as of that quarter.
4. A year-over-year growth rate of less than 9.02 percent is forecasted.
5. OctaFinance gave Stryker stock a “neutral” rating after taking Ms. Stryker’s sale into account, with the stock price up 23.34 percent over the past 200 days.
More articles on orthopedic devices:
5 key notes on Invuity’s new CFO
FDA clears MAKO technology for total knee replacement
K2M, InVivo Therapeutics, Zimmer & more—19 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
